Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SIM 0237

Next Previous
Drug Profile

SIM 0237

Alternative Names: SIM-0237; SIM-237

Latest Information Update: 02 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Simcere Pharmaceutical Group
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 15 replacements; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bladder cancer; Solid tumours

Most Recent Events

  • 17 Dec 2024 Jiangsu Simcere Pharmaceutical terminates Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China and the US (IV), due to an internal business decision, and not based on safety or regulatory considerations (NCT05781360)
  • 23 Jan 2024 Phase-I clinical trials in Bladder cancer (Combination therapy) in China (Intravesicular) (NCT06186414)
  • 23 Jan 2024 Phase-I clinical trials in Bladder cancer (Monotherapy) in China (Intravesicular) (NCT06186414)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top